Monocyte stimulation resulting in interleukin-1 (IL-1) production can be accomplished with many different compounds. Yet little insight into the negative regulation of IL-1 production is available. Therefore, this research proposal is a two-phase project aimed at elucidating control of production of this monokine. In phase one, we will begin to identify in monocytes 1) time course of IL-1 protein and gene expression, 2) the effects of different stimuli on differential IL-1 gene expression, 3) pharmacological inhibition of IL-1 protein or gene expression, 4) the role of arachidonic acid metabolites in IL-1 protein or gene expression, 5) lymphocytes and lymphocyte products' place in regulation of IL-1 protein or gene expression. Experiments will be performed on peripheral blood monocytes stimulated with LPS or other IL-1 inducers. Inhibition experiments will evaluate commonly used immunomodulatory drugs (dexamethasone and cyclosporin A), cyclooxygenase (indomethacin) and lipoxygenase (U60) inhibition of arachidonic metabolism. Analysis of IL-1 protein expression will require use of standard tissue culture techniques for monocyte isolation, mouse thymocyte bioassays for IL-1 functional quantification and Northern analysis of total cellular RNA using a synthetic oligonucleotide directed against IL-1 mRNA. In phase two, application of immunological control mechanisms will be applied to alveolar macrophage and sarcoidosis, where we hypothesize that abnormal IL-1 regulation may lead to permanent disability. We will identify in normal alveolar macrophages and in sarcoidosis 1) time course of IL-1 protein and gene expression, 2) the effects of different stimuli on differential IL-1 gene expression, 3) pharmacological inhibition of IL-1 protein and gene expression, 4) the role of normal lymphocytes, their products and those in sarcoidosis in regulating IL-1 protein and gene expression. These studies will be accomplished through use of standard mouse thymocyte assays and Northern analysis of IL-1 RNA. With pharmacologically relevant inhibitors studied in detail, new therapeutic options will then become available for immunologically mediated lung disease, such as sarcoidosis. Regulation of IL-1 production may be very important in altering prognosis and functional impairment in these diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Physician Scientist Award (K11)
Project #
5K11HL001575-04
Application #
3087268
Study Section
(SRC)
Project Start
1988-07-01
Project End
1991-06-30
Budget Start
1989-07-01
Budget End
1990-06-30
Support Year
4
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Kern, J A; Robinson, R A; Gazdar, A et al. (1992) Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Am J Respir Cell Mol Biol 6:359-63
Kern, J A; Schwartz, D A; Nordberg, J E et al. (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-7
Weiner, D B; Nordberg, J; Robinson, R et al. (1990) Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50:421-5
Elias, J A; Freundlich, B; Adams, S et al. (1990) Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma. Ann N Y Acad Sci 580:233-44
Elias, J A; Reynolds, M M; Kotloff, R M et al. (1989) Fibroblast interleukin 1 beta: synergistic stimulation by recombinant interleukin 1 and tumor necrosis factor and posttranscriptional regulation. Proc Natl Acad Sci U S A 86:6171-5
Elias, J A; Trinchieri, G; Beck, J M et al. (1989) A synergistic interaction of IL-6 and IL-1 mediates the thymocyte-stimulating activity produced by recombinant IL-1-stimulated fibroblasts. J Immunol 142:509-14